Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non-Current Assets (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Other Non-Current Assets data on record, last reported at $549000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 2.14% year-over-year to $549000.0; the TTM value through Sep 2025 reached $549000.0, down 2.14%, while the annual FY2024 figure was $462000.0, 12.5% down from the prior year.
  • Other Non-Current Assets reached $549000.0 in Q3 2025 per PLX's latest filing, up from $520000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.1 million in Q4 2021 and bottomed at $459000.0 in Q1 2025.
  • Average Other Non-Current Assets over 5 years is $1.1 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: rose 18.85% in 2021, then crashed 58.33% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $2.1 million in 2021, then tumbled by 39.0% to $1.3 million in 2022, then crashed by 58.33% to $528000.0 in 2023, then decreased by 12.5% to $462000.0 in 2024, then rose by 18.83% to $549000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $549000.0 in Q3 2025, $520000.0 in Q2 2025, and $459000.0 in Q1 2025.